GlassScriptPhysician profile
David J Anschel
NPI 1689620387
$27,202.18
in general payments reported to CMS, 2019-2025
21 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $1,651 · 2021: $12K · 2022: $8,179 · 2023: $592 · 2024: $2,525 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,755 · Travel and Lodging: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,755.07 |
| Travel and Lodging | $1,590.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $19,640.48 | 2020-2022 | |
| Medtronic, INC. | $2,295.91 | 2024 | Stealthstation S8 Platform |
| Livanova USA, INC. | $1,379.95 | 2019-2021 | |
| Sk Life Science, INC. | $1,290.40 | 2020-2025 | Xcopri |
| Greenwich Biosciences, INC. | $445.22 | 2019-2021 | |
| Biogen, INC. | $440.59 | 2019-2023 | Vumerity |
| Ucb, INC. | $197.04 | 2024-2025 | |
| Viatris Specialty LLC | $186.11 | 2025 | Yupelri |
| Neuropace, INC. | $157.60 | 2022-2024 | |
| Cadwell Industries, INC | $156.00 | 2023 | |
| Sunovion Pharmaceuticals INC. | $149.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $131.23 | 2023 | Calquence |
| Alexion Pharmaceuticals, INC. | $124.96 | 2019 | |
| Abbvie INC. | $124.77 | 2023 | Ubrelvy, Qulipta |
| Aquestive Therapeutics, INC. | $124.77 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $118.70 | 2024-2025 | |
| Lundbeck LLC | $96.56 | 2025 | Vyepti |
| Zogenix INC. | $88.68 | 2021 | |
| Acadia Pharmaceuticals INC | $24.00 | 2025 | Daybue |
| Abbott Laboratories | $17.92 | 2019 | |
| Biomarin Pharmaceutical INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Anschel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.